The Poisoned Patient Nobody Can Name: A Systematic Approach to Unknown Toxin Ingestion

The Poisoned Patient Nobody Can Name:

A Systematic Approach to Unknown Toxin Ingestion

Dr Neeraj Manikath , claude.ai

📋  Abstract Unknown toxin ingestion represents one of the most cognitively demanding and time-pressured scenarios in acute medicine. With over four million toxic exposures reported annually in high-income countries alone, and a significant proportion presenting without a clear history, the clinician's ability to synthesise pattern recognition, bedside toxidrome analysis, and rational antidote selection is literally life-saving. This grand rounds review provides a systematic, evidence-based framework for the diagnosis and management of the poisoned patient with an unidentified agent. We address toxidrome identification, the rational use of decontamination, antidote selection, escalation thresholds, and current controversies including high-dose insulin therapy, lipid emulsion rescue, and the role of extracorporeal elimination. Clinical pearls, bedside hacks, and a toxidrome reference table are integrated throughout for immediate clinical applicability.   Key Words: Toxidrome, unknown poisoning, antidote therapy, decontamination, toxicology, overdose, emergency medicine

 

1. The Case That Started It All: A Clinical Introduction

🏥  Clinical Vignette A 34-year-old woman is wheeled into the emergency department by bystanders who found her unresponsive near a park bench. She has no identification. Her Glasgow Coma Scale score is 7 (E2V2M3). Paramedics report empty bottles of an unknown liquid nearby. On examination: heart rate 52 bpm, BP 88/54 mmHg, respiratory rate 6 breaths/min, SpO2 84% on room air, temperature 35.2°C. Her pupils are 1 mm bilaterally and pinpoint. There are no signs of trauma. The triage nurse asks: 'What do we give her?'

 

This scenario — collapsed patient, unknown substance, no collateral history — is not a rarity. Data from the American Association of Poison Control Centers' 2022 National Poison Data System report document over 2.2 million human exposure calls in that single year, with nearly 12% involving unidentified substances.1 In the United Kingdom, TOXBASE queries for 'unknown agent' consistently rank among the top five categories year on year. The challenge is not academic; it is immediate, visceral, and consequential.

What separates the master clinician from the anxious registrar in this setting is not encyclopaedic memorisation of every possible poison. It is the ability to recognise constellations — toxidromes — and translate them into rapid, high-confidence clinical decisions. The vignette above almost certainly represents opioid toxicity: the triad of coma, respiratory depression, and miosis is pathognomonic. Naloxone administered promptly would be both diagnostic and therapeutic.

Yet even this 'obvious' case carries pitfalls. What if she also ingested a tricyclic antidepressant? What if the miosis is from pontine haemorrhage rather than opioids? What if naloxone precipitates a withdrawal-driven seizure? This review is designed to equip the postgraduate trainee and practicing consultant with the knowledge to navigate these uncertainties systematically, decisively, and safely.

2. Pathophysiology — The Clinically Actionable Essentials

A full mechanistic review of every toxin is neither possible nor useful at the bedside. What matters is understanding enough pharmacodynamics and toxicokinetics to predict the time course and manage the complications.

2a. Receptor-Level Pharmacodynamics: Why Toxidromes Exist

Most clinically important poisonings act through a limited repertoire of receptor systems. The opioid, cholinergic, adrenergic, GABAergic, and sodium/potassium channel systems account for the vast majority of life-threatening presentations. Toxidromes are the clinical expression of receptor saturation:

•        Opioid receptor agonism (μ, κ, δ): CNS depression, respiratory depression, miosis, reduced GI motility.

•        Cholinergic excess (muscarinic and nicotinic): SLUDGE (salivation, lacrimation, urination, defaecation, GI distress, emesis) plus bronchospasm, bradycardia, miosis, and nicotinic features (muscle fasciculations, weakness, paralysis).

•        Sympathomimetic excess (noradrenaline/dopamine): tachycardia, hypertension, agitation, mydriasis, hyperthermia, diaphoresis.

•        Anticholinergic blockade: tachycardia, mydriasis, flushing, dry skin, hyperthermia, urinary retention, ileus, delirium.

•        Sodium channel blockade (e.g., TCAs, local anaesthetics, flecainide): QRS widening, hypotension, seizures.

•        Potassium channel blockade (e.g., antipsychotics, antihistamines, methadone): QTc prolongation, torsades de pointes.

2b. Toxicokinetics: Timing Is Everything

Understanding the toxicokinetic phases helps predict when the patient is most at risk and when a patient who appears stable may be about to deteriorate:

⏱  Toxicokinetic Phase Framework Absorption phase: Patient may appear deceptively well; peak toxicity is ahead. Most oral poisons peak within 1–6 hours, but modified-release formulations may peak at 12–24 hours. Distribution phase: Volume of distribution determines how much free drug is available; highly lipid-soluble agents (e.g., TCAs, digoxin) have enormous Vd and are NOT cleared by haemodialysis. Elimination phase: Half-life governs duration; in overdose, zero-order kinetics may apply (paracetamol, phenytoin, alcohol) — small increases in dose cause disproportionately large increases in AUC. Enterohepatic recirculation: Some agents (e.g., theophylline, digoxin) re-enter the gut; multi-dose activated charcoal is logical here.

 

The concept of the 'therapeutic window' is particularly relevant: in clinical overdose, the patient may initially sit within a tolerable zone of exposure before autoinduction of metabolism is overwhelmed or delayed absorption delivers a second wave of toxin. This explains late deterioration in seemingly stable patients — one of the most dangerous patterns in toxicology.

2c. The Anion Gap and Osmolar Gap as Metabolic Fingerprints

In the unconscious patient with an unknown ingestion, metabolic biochemistry provides clues unavailable from clinical examination alone. A raised anion gap (>12 mmol/L, corrected for albumin) suggests accumulation of an unmeasured anion. The mnemonic MUDPILES (Methanol, Uraemia, Diabetic ketoacidosis, Propylene glycol, Isoniazid/Iron, Lactic acidosis, Ethylene glycol, Salicylates) captures the major toxic causes. The osmolar gap (measured – calculated osmolality >10 mOsm/kg) in the context of a raised anion gap is highly specific for toxic alcohol ingestion — methanol or ethylene glycol — early in the clinical course before the alcohols are fully metabolised to their toxic acids.

3. 🪙 Clinical Pearls — Counterintuitive High-Yield Observations

🪙  Pearl 1: Naloxone Is a Diagnostic Tool, Not Just a Therapy A partial response to naloxone does not exclude opioids — it may mean mixed ingestion (e.g., opioid + benzodiazepine), a partial agonist (buprenorphine requires higher doses), or a long-acting opioid (methadone) requiring infusion rather than bolus dosing. Full restoration of consciousness is not the goal; adequate respiratory drive is.

 

🪙  Pearl 2: The Vital Signs Tell You Which Toxidrome Before the History Does Construct a 'vital signs toxidrome matrix' before opening the chart. HR+BP+Temp+RR+Pupils gives you 80% of the diagnosis. Bradycardia + hypotension + normal pupils: think beta-blockers, CCBs, digoxin, or clonidine. Tachycardia + hypertension + mydriasis + hyperthermia: think sympathomimetics or serotonin syndrome.

 

🪙  Pearl 3: Miosis Is Not Pathognomonic for Opioids Organophosphate poisoning, clonidine, antipsychotics, and pontine haemorrhage all cause miosis. In the absence of respiratory depression and a response to naloxone, pursue alternative diagnoses. Perform a fundus examination and order a CT head before committing to a purely opioid diagnosis.

 

🪙  Pearl 4: QRS Widening Trumps QTc in Acute Overdose Triage A QRS > 100 ms in a poisoned patient is a medical emergency signalling sodium channel blockade — most commonly TCA overdose. Bicarbonate is antidotal. A widened QRS predicts seizures and ventricular arrhythmia with greater specificity than a prolonged QTc in the acute setting.

 

🪙  Pearl 5: The Patient Who Is 'Fine' Needs Watching Longest In paracetamol overdose, salicylate overdose, and toxic alcohol ingestion, the patient may appear clinically well for hours while devastating hepatotoxicity, cerebral oedema, or metabolic acidosis silently evolves. The absence of symptoms is not reassurance; the time and dose are.

 

4. 🦪 Oysters — Hidden Gems Most Clinicians Miss

🦪  Oyster 1: The 'Intermediate Syndrome' in Organophosphate Poisoning Between the acute cholinergic crisis (days 1–2) and the delayed peripheral neuropathy, OP-poisoned patients can develop acute respiratory failure from proximal muscle weakness on days 1–4 — the 'intermediate syndrome'. They may appear to be recovering clinically, then crash. Bedside neck flexion power testing and respiratory monitoring are mandatory even in improving patients.

 

🦪  Oyster 2: Clonidine Mimics Opioid Toxidrome Perfectly Clonidine overdose produces coma, miosis, bradycardia, and respiratory depression — an opioid toxidrome clone. It will NOT respond to naloxone. The giveaway: relative hypertension before hypotension (sympathetic burst from alpha-2 agonism), cyclical blood pressure swings, and resistance to naloxone at any dose. Clonidine is ubiquitous in antihypertensive regimens; pill counts from family members are invaluable.

 

🦪  Oyster 3: Digoxin Toxicity and the 'K+ Paradox' In ACUTE digoxin poisoning, hyperkalaemia is a marker of severity — serum K+ > 5.5 mEq/L is associated with 50% mortality without Fab treatment. In CHRONIC toxicity (more common, more insidious), hypokalaemia from diuretics potentiates toxicity. The same drug, opposite electrolyte signatures, and different management priorities. Do not treat the hyperkalaemia of acute digoxin poisoning with calcium — it may precipitate 'stone heart.'

 

🦪  Oyster 4: Serotonin Syndrome vs. NMS — the Clonus Clue Both cause hyperthermia, altered consciousness, and autonomic instability. The distinguishing feature of serotonin syndrome is clonus — especially inducible ankle clonus and ocular clonus (spontaneous rhythmic lateral eye movements). NMS has lead-pipe rigidity without clonus. This distinction matters enormously: dopamine blockade with antipsychotics worsens serotonin syndrome, and serotonin agents worsen NMS.

 

🦪  Oyster 5: Beta-blocker and CCB Overdose — Glucose as a Discriminator In a haemodynamically unstable bradycardia: hypoglycaemia suggests beta-blocker toxicity (insulin suppression); normoglycaemia or hyperglycaemia suggests CCB toxicity (alpha-cell sparing with inhibited insulin secretion from pancreatic beta-cells). This bedside glucose check takes 30 seconds and meaningfully narrows your differential before any drug levels return.

 

5. ⚡ Clinical Hacks & Tips — Master Clinician Shortcuts

5a. The Toxidrome-First Approach

Before ordering a panel of drug levels, ask: 'Can I identify a toxidrome from what I see right now?' In the majority of cases, a confident toxidrome identification will guide immediate management faster and more usefully than any lab test. Structure your bedside assessment as:

•        Autonomic signature: HR, BP, temperature, skin (dry/wet), pupil size

•        Neuromuscular signature: tone, reflexes, clonus, tremor, fasciculations

•        GI signature: bowel sounds, vomiting, diarrhoea, salivation

•        Respiratory signature: rate, depth, bronchospasm

5b. The ‘12-Lead ECG as Toxicology Screen’ Trick

Request a 12-lead ECG within the first five minutes. Four key findings immediately narrow your differential:

•        QRS > 100 ms: sodium channel blocker (TCA, flecainide, cocaine, quinine, chloroquine)

•        QTc > 500 ms: potassium channel blocker (antipsychotics, methadone, sotalol, antihistamines)

•        Bradycardia + AV block: digoxin, beta-blocker, CCB, clonidine, cholinergic

•        Bidirectional VT: digoxin toxicity until proven otherwise

5c. Calculating the Osmolar Gap at the Bedside

Calculated osmolality = (2 × Na) + (Glucose/18) + (Urea/2.8). The difference between measured serum osmolality and this calculated value is the osmolar gap. A gap > 10 mOsm/kg in a comatose patient with metabolic acidosis is ethylene glycol or methanol until proven otherwise — do not wait for levels; start fomepizole empirically.

5d. Modified Glasgow Coma Scale for Toxicology

The standard GCS does not capture toxin-specific features. Augment it with pupil reactivity, limb tone, and respiratory rate at the same time point. A GCS of 10 with bilateral dilated fixed pupils and absent bowel sounds tells a very different story than a GCS of 10 with intact reflexes and normal pupils.

5e. Decontamination Decision in 30 Seconds

⚡  Activated Charcoal Decision Rule Give if: Ingestion of a charcoal-adsorbable agent within 1–2 hours, airway is protected (or can be protected), no ileus, no corrosive ingestion. Do NOT give if: Corrosives, hydrocarbons, metals (iron, lithium, arsenic), alcohols — charcoal does not bind these. Consider multi-dose activated charcoal (MDAC) for: Theophylline, carbamazepine, dapsone, quinine, phenobarbitone — agents with significant enterohepatic or enteroenteric circulation. The 1-hour window is a guideline, not an absolute — in modified-release formulations, the window extends. Clinical judgement applies.

 

6. State-of-the-Art Updates — What Has Changed in Toxicology Practice

6a. High-Dose Insulin Euglycaemic Therapy (HIET) — Now First-Line for CCB and BB Overdose

Perhaps the most significant paradigm shift in acute toxicology over the last decade is the elevation of high-dose insulin euglycaemic therapy (HIET) from a rescue manoeuvre to a first-line intervention in haemodynamically compromised calcium channel blocker (CCB) and beta-blocker (BB) overdose.10 The rationale is elegant: CCB and BB poisoning induce a state of cardiogenic shock driven partly by impaired myocardial glucose metabolism. In high-dose toxicity, the cardiac myocyte becomes a near-obligate fat metaboliser; insulin shifts substrate utilisation back to glucose, enhancing contractility.

The current recommended protocol: Insulin 1 unit/kg IV bolus, followed by 0.5–1 unit/kg/hour infusion, with a simultaneous 25 g (50 mL of 50%) dextrose bolus, and continuous glucose infusions titrated to maintain euglycaemia (4–8 mmol/L). Potassium replacement is mandatory; hypokalaemia is predictable and dangerous. Some case series and institutional protocols now use doses exceeding 2–3 units/kg/hour in refractory cases.

6b. Intravenous Lipid Emulsion Therapy (ILE): Promise and Pragmatism

Lipid emulsion (Intralipid 20%) was first used to rescue bupivacaine-induced cardiac arrest. Its putative mechanism — a 'lipid sink' that sequesters lipophilic drugs away from cardiac tissue — has attracted enthusiasm, but the evidence base remains largely observational.11 ILE is currently recommended for life-threatening toxicity from local anaesthetics and may be considered for other highly lipid-soluble agents (TCAs, CCBs, beta-blockers) when conventional therapy has failed. The protocol: 1.5 mL/kg of 20% lipid emulsion IV over 1 minute, then 0.25 mL/kg/minute infusion for 30–60 minutes. The critical caveat: ILE can interfere with immunoassay drug screens, lipid monitoring, and ECMO circuits — sequence your interventions accordingly.

6c. Extracorporeal Removal — EXTRIP Workgroup Guidance

The EXTRIP (Extracorporeal Treatments In Poisoning) workgroup has published systematic reviews and recommendations on when haemodialysis or haemoperfusion is indicated in specific poisonings. Key takeaways: Haemodialysis is strongly recommended in severe salicylate, metformin-associated lactic acidosis, methanol, and ethylene glycol toxicity. Lithium toxicity warrants HD when levels are high AND there are severe neurological features. Digoxin, TCAs, and most antidepressants have high Vd and are NOT significantly removed by HD — Fab fragments and supportive care remain the mainstay.

6d. Revised N-Acetylcysteine (NAC) Protocols for Paracetamol Poisoning

The traditional three-bag, 21-hour IV NAC protocol has been under revision. Studies including the SNAP trial have shown that a two-bag modified-duration protocol (200 mg/kg over 4 hours, then 100 mg/kg over 16 hours) produces equivalent outcomes with a significantly lower rate of anaphylactoid reactions — which occur in up to 20% of patients on the traditional protocol, predominantly during the first rapid infusion.14 Oral NAC remains an alternative in stable patients without vomiting. The Rumack-Matthew nomogram remains the standard for risk stratification, but ingestion time uncertainty (very common in intentional overdose) should prompt more liberal treatment thresholds.

6e. Point-of-Care Urine Drug Screens — Know the Limitations

Immunoassay urine drug screens remain widely used but are deeply misunderstood. They detect drug class, not specific agents. Synthetic opioids (fentanyl, tramadol) are commonly negative on standard opiate panels. MDMA may be negative on amphetamine screens. Conversely, false positives are legion: quinolones for opiates, dextromethorphan for PCP, ranitidine for amphetamines. A negative drug screen never excludes poisoning; a positive screen does not identify the specific agent or confirm causation. Gas chromatography-mass spectrometry (GC-MS) is definitive but takes hours and is rarely available in real time.

7. Diagnostic Nuances — What Separates Good From Great Clinicians

7a. The History Is Everything — Even When There Is None

No history from the patient does not mean no history. Every unconscious patient deserves a collateral interview protocol:

•        Call family/friends: What medications are in the household? Any psychiatric history? Substance use? Any conflict or distress in the past 48 hours?

•        Review pharmacy records: Most hospital systems can access dispensed prescription data. A patient on methadone maintenance, TCA antidepressants, or warfarin changes your entire management.

•        Check the scene: Paramedics are invaluable. Empty bottles, pill packets, drug paraphernalia, or the odour of alcohol can clinch a diagnosis.

•        Previous ED presentations: Repeat self-harm attempts, documented drug use, and prior antidote administration are all relevant.

7b. Smell as a Diagnostic Tool

Several toxins carry distinctive odours that are specific enough to be diagnostically meaningful:

•        Bitter almonds / marzipan: Cyanide (also cassava ingestion)

•        Garlic / onions: Organophosphates (DMSO or thioether metabolites); also arsenic

•        Alcohol: Ethanol, but also ethylene glycol (sweet-smelling) and isopropanol

•        Pear drops (acetone): Diabetic ketoacidosis — and also isopropanol poisoning

•        Wintergreen: Methyl salicylate (a highly concentrated form of salicylate)

•        Moth balls: Camphor or naphthalene

7c. The Skin as a Toxicology Window

Cutaneous findings provide real-time toxidrome data without any laboratory requirement:

•        Diaphoresis + warm skin: Sympathomimetic or serotonin syndrome (autonomic hyperactivity); also salicylate toxicity

•        Dry, hot, flushed skin: Anticholinergic toxidrome

•        Cyanosis resistant to oxygen: Methaemoglobinaemia (dapsone, nitrites, aniline dyes, primaquine)

•        Track marks: IV drug use; also insulin injection sites

•        Blistering in pressure areas (‘barbiturate blisters’): Prolonged immobility from CNS depressant overdose

7d. Investigations That Are Cheap but Underused

A urine dipstick in a poisoned patient is frequently revelatory: oxalate crystalluria in ethylene glycol poisoning; myoglobinuria in rhabdomyolysis (from hyperthermia, prolonged seizures, or serotonin syndrome); haematuria suggesting systemic toxicity. A venous blood gas provides pH, lactate, bicarbonate, and glucose in minutes — enough to confirm a toxic metabolic acidosis and guide urgent escalation.

8. Management Intricacies — Drugs, Doses, Timing, and Pitfalls

8a. Airway Management in the Poisoned Patient

The decision to intubate in poisoning is nuanced and context-specific. Mechanical ventilation is not intrinsically beneficial in most overdoses — it commits the patient to sedation, ICU admission, and ventilator-associated complications. However, it is mandatory when:

•        GCS ≤ 8 with absent gag reflex and aspiration risk

•        Respiratory failure unresponsive to antidotal therapy

•        Refractory seizures requiring paralysis and EEG monitoring

•        Need for gastric lavage in a non-cooperating patient

When intubating a poisoned patient, ketamine is the preferred induction agent in sympathomimetic and serotonin toxidrome (it does not suppress catecholamines). Avoid succinylcholine in organophosphate poisoning (pseudocholinesterase deficiency prolongs blockade dramatically) — use rocuronium instead.

8b. Antidote Sequencing — The Correct Order Matters

In multi-drug ingestion (the norm rather than the exception in intentional overdose), antidote sequencing requires careful thought. The general principle: treat the most immediately life-threatening condition first. An algorithm:

•        1. Oxygen, IV access, monitoring: Universal.

•        2. Dextrose 50 mL of 50% IV: If hypoglycaemic or unknown (glucose is essential metabolic substrate; thiamine 100 mg IV before dextrose if alcoholism suspected).

•        3. Naloxone: If opioid toxidrome is present (start 0.4 mg IV, titrate up to 2 mg; in buprenorphine: 2–10 mg may be needed).

•        4. Bicarbonate: If QRS > 100 ms or refractory hypotension in suspected TCA — 1–2 mEq/kg IV bolus, targeting arterial pH 7.50–7.55.

•        5. Atropine + pralidoxime: If cholinergic toxidrome. Atropine is titrated to drying of secretions, not just heart rate. Doses of 20–40 mg in the first hour are not uncommon in severe OP poisoning.4

8c. Pitfalls in Antidote Use

⚠️  Critical Antidote Pitfalls FLUMAZENIL: Avoid in chronic benzodiazepine users (precipitates status epilepticus), TCA co-ingestion, or elevated ICP. Its diagnostic value rarely justifies its risk in undifferentiated overdose.7 NALOXONE: Do not give large boluses in opioid-dependent patients — precipitates acute withdrawal, vomiting with aspiration risk, pulmonary oedema, and dangerous agitation. Titrate small doses (0.04–0.1 mg) in known opioid users. PHYSOSTIGMINE: Use only when anticholinergic toxidrome is the definitive diagnosis and QRS is normal. In TCA overdose, physostigmine can precipitate seizures and asystole. CALCIUM in digoxin overdose: Historically contraindicated (feared 'stone heart'); however this is now considered theoretical. In extremis, calcium may be used, but Fab should be given simultaneously.

 

8d. Managing the Hyperthermic Poisoned Patient

Hyperthermia in poisoning is an emergency. At core temperatures above 41°C, protein denaturation causes organ failure within minutes to hours. Rapid external cooling (ice packs to axillae, groin, neck; cool mist + fan) is the immediate step. Pharmacological cooling with benzodiazepines (for sympathomimetic agitation) and cyproheptadine (for serotonin syndrome) are specific. Dantrolene is indicated in malignant hyperthermia and may have a role in severe NMS, but has no evidence in serotonin syndrome. Antipyretics (paracetamol, NSAIDs) are ineffective — the hyperthermia is not prostaglandin-mediated; it is from uncoupled heat production.

9. When to Escalate / When to Watch — Threshold Decision-Making

9a. Criteria for ICU Admission in the Poisoned Patient

Not every overdose requires intensive care. The decision to escalate should be driven by physiological parameters, toxin characteristics, and trajectory rather than anxiety or resource availability. Escalate to ICU when:

•        GCS ≤ 10 with signs of airway compromise or deteriorating trajectory

•        Haemodynamic instability not responding to initial resuscitation

•        Seizures (especially refractory or recurrent)

•        Core temperature > 40°C

•        Significant metabolic acidosis (pH < 7.1 or lactate > 8 mmol/L)

•        QRS > 120 ms or refractory arrhythmia

•        Need for antidote infusion (e.g., HIET, NAC, pralidoxime, glucagon)

•        Agent with known delayed toxicity (modified-release CCBs, paracetamol with delayed presentation, toxic alcohols)

9b. Safe Discharge Criteria — The Observation Window

The minimum observation period depends entirely on the toxin:

•        Immediate-release opioids: 6 hours of observation after last symptomatic episode

•        Modified-release opioids (methadone, tramadol ER): 24 hours minimum

•        Paracetamol: Treat per nomogram; 24 hours post-NAC if nomogram treatment complete

•        Modified-release CCBs/BBs: 24 hours minimum, with continuous cardiac monitoring

•        Symptomatic TCA overdose: Minimum 24 hours; discharge only after 12+ hours asymptomatic on normal ECG

📋  The Daly Risk Assessment Framework A structured risk assessment (Daly et al., 2006) integrates four dimensions: (1) the inherent toxicity of the agent, (2) the dose ingested relative to toxic threshold, (3) the time elapsed since ingestion, and (4) individual patient factors (renal/hepatic function, co-ingestion, susceptibility). Applying this framework systematically converts a clinical gestalt into a communicable, defensible, reproducible risk decision.

 

9c. When to Call the Toxicologist

Every hospital should have a clear pathway to clinical toxicology expertise. Call early when: the agent is unusual or unidentified despite systematic assessment; there is a mixed picture with competing toxidromes; antidote use carries significant risk; the patient is pregnant; paediatric exposure is involved; or the patient is deteriorating despite apparently correct treatment. National Poisons Information Service (NPIS in UK) and Poison Control Center consultation (US) are available 24/7 and are dramatically underutilised.

10. Summary — The TOXIN Mnemonic & Quick-Reference Table

🪙  The TOXIN Framework for Unknown Ingestion T — Toxidrome: Identify the clinical syndrome from vital signs + examination (opioid / cholinergic / anticholinergic / sympathomimetic / mixed) O — Observe the ECG: QRS width, QTc, rate, rhythm — your fastest toxicology screen X — eXclude alternatives: Non-toxic causes of coma (head injury, stroke, metabolic, sepsis) must be actively excluded I — Investigate strategically: VBG, BMP, paracetamol + salicylate levels, osmolar gap, urine dip, serum lactate; not a scattergun drug screen N — Neutralise and support: Antidote if available and indicated; decontamination if within window; aggressive supportive care always

 

Quick-Reference Toxidrome & Management Table

Toxidrome / Agent	Key Features	Antidote / First-Line Rx	Critical Pitfall
Opioids/Sedatives	Bradypnoea, miosis, CNS depression	Naloxone 0.4–2 mg IV; flumazenil only if pure BZD & no seizure risk	Respiratory arrest, aspiration
Cholinergic (OP/Carbamate)	SLUDGE/DUMBELS, miosis, bronchospasm	Atropine 2–4 mg IV q5–10 min + Pralidoxime 1–2 g IV over 15–30 min	Intermediate syndrome (Day 1–4 delayed)
Anticholinergic	Flushed, dry, tachycardia, mydriasis, delirium	Physostigmine 1–2 mg IV slowly (only if diagnosis certain)	QTc prolongation; avoid if TCA suspected
Sympathomimetics	Agitation, tachycardia, hypertension, diaphoresis	Benzodiazepines (titrated); phentolamine for refractory HTN	Hyperthermia → rhabdomyolysis → AKI
Tricyclic Antidepressants	Wide QRS, hypotension, seizures, anticholinergic	NaHCO3 1–2 mEq/kg IV bolus; serum pH 7.45–7.55	Rebound toxicity; no flumazenil
Serotonin Syndrome	Clonus, hyperreflexia, hyperthermia, agitation	Cyproheptadine 12 mg PO/NG; BZD; cool aggressively	Mimics NMS; differentiate before Rx
Salicylates	High anion gap, resp. alkalosis + met. acidosis, tinnitus	NaHCO3 infusion + urinary alkalinisation; HD if severe	Delayed peak with enteric-coated tabs
Beta-blockers/CCBs	Bradycardia, hypotension, HB block, normo-glycaemia (BB)	High-dose insulin (1 U/kg bolus then 0.5–1 U/kg/h) + lipid emulsion	Calcium not first-line in CCB overdose
Digoxin/Cardiac Glycosides	Bradyarrhythmias, AV block, yellow-green halo, nausea	Digoxin-specific Fab 10–20 vials empirical (severe)	K+ paradox: hyperK in acute vs. hypoK in chronic
Paracetamol	Phase I–IV hepatotoxicity; initially well	N-acetylcysteine IV per Rumack-Matthew nomogram	Therapeutic misadventure most common cause

 

11. References

1. Gummin DD, Mowry JB, Beuhler MC, et al. 2022 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 40th Annual Report. Clin Toxicol (Phila). 2023;61(10):717–939.

2. Barheine JM, Levine M. Unknown toxin exposure: a systematic approach to diagnosis and management. Emerg Med Clin North Am. 2022;40(2):297–315.

3. Olson KR, Anderson IB, Benowitz NL, et al., editors. Poisoning & Drug Overdose. 7th ed. New York: McGraw-Hill; 2018.

4. Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008;371(9612):597–607.

5. Holstege CP, Baer AB. The emergency physician's role in managing the unknown poisoned patient. Emerg Med Clin North Am. 2021;39(1):1–23.

6. Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med. 2018;71(3):314–325.e1.

7. Sivilotti ML. Flumazenil, naloxone and the comatose patient. Br J Clin Pharmacol. 2016;81(3):428–436.

8. Levine M, Brooks DE, Truitt CA, Wolk BJ, Boyer EW, Ruha AM. Toxicology in the ICU: Part 1: General overview and approach to treatment. Chest. 2011;140(3):795–806.

9. Lavonas EJ, Drennan IR, Gabrielli A, et al. Part 10: Special circumstances of resuscitation: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015;132(18 Suppl 2):S501–S518.

10. Graudins A, Lee HM, Druda D. Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies. Br J Clin Pharmacol. 2016;81(3):453–461.

11. Cave G, Harvey M. Intravenous lipid emulsion as antidote beyond local anesthetic toxicity: a systematic review. Acad Emerg Med. 2009;16(9):815–824.

12. Juurlink DN. Managing the patient with acute drug overdose. CMAJ. 2023;195(26):E909–E917. [Epub ahead of print].

13. Daly FFS, Little M, Murray L. A risk assessment based approach to the management of acute poisoning. Emerg Med J. 2006;23(5):396–399.

14. Bateman DN, Dear JW, Thanacoody HK, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet. 2014;383(9918):697–704.

15. Seger DL. Clonidine toxicity revisited. J Toxicol Clin Toxicol. 2002;40(2):145–155.

 

This article is intended for educational purposes. Clinical decisions should be made in conjunction with local protocols, specialist consultation, and individual patient circumstances.